VB119 ( DrugBank: - )


1 disease
IDDisease name (Link within this page)Number of trials
222Primary nephrotic syndrome1

222. Primary nephrotic syndrome


Clinical trials : 285 Drugs : 285 - (DrugBank : 108) / Drug target genes : 62 - Drug target pathways : 191
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT04652570
(ClinicalTrials.gov)
May 5, 202123/11/2020Efficacy and Safety of VB119 in Subjects With Membranous NephropathyA Phase 1b/2a Study of VB119 in Adult Subjects With Primary Membranous NephropathyMembranous NephropathyDrug: VB119ValenzaBio, Inc.NULLRecruiting18 YearsN/AAll30Phase 1/Phase 2United States;United Kingdom